AUTHORS
Doug Kass
Doug Kass is the president of Seabreeze Partners Management Inc. Until 1996, he was senior portfolio manager at Omega Advisors, a $6 billion investment partnership. Before that he was executive senior vice president and director of institutional equities of First Albany Corporation and JW Charles/CSG. He also was a General Partner of Glickenhaus & Co., and held various positions with Putnam Management and Kidder, Peabody. Kass received his bachelor's from Alfred University, and received a master's of business administration in finance from the University of Pennsylvania's Wharton School in 1972. He co-authored "Citibank: The Ralph Nader Report" with Nader and the Center for the Study of Responsive Law and currently serves as a guest host on CNBC's "Squawk Box."
A Note from Doug: Current strategies and actionable trade ideas -- all on one dynamic platform built exclusively for active trades. From sudden sell-offs to sudden spikes, Real Money Pro arms you with crucial analysis -- at a rapid fire, professional pace -- to help you make sound trading decisions -- every day, every hour, and every minute. Join me and my team of professional traders for unique perspectives and breakthrough investment opportunities.
Try it Now! Free for 14 Days.
Follow @dougkass
Recent Articles By The Author
The Book of Boockvar
Dancing on the fine line/up to 90k/Sentiment/Notable quotes While I don't think the news from the Bank of Canada was that much of surprise as their new rate is still at 4.5%, it was what Governor Macklem said in his press conference that highlights ...
The Danger of Trading a Headline
At 4:10 pm Wednesday, IBM traded at $144.50: View Chart » View in New Window »
My Cannabis Tweet of the Day
The weed carnage now begins: And now (as I have warned) the cannabis business/state closures and write-offs start.... https://t.co/6AOsvwnH7f @realmoney @dougkass @seabreezelp — Dougie Kass (@DougKass) January 26, 2023
Selected Market Movers
Upside - +30% (earnings, guidance) - +11% (ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer's Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial) - +9.2% (earnings, guidance) - +8.1% (to replace VIVO in S&P SmallCap...
On the Cautious Side
Liz from SOFI: ¿New blog post: "Walks Like a Duck, Quacks Like a Duck" on the mounting evidence that keeps me on the cautious side. These are signals we can't ignore. https://t.co/yFIfmFSrLM — Liz Young (@LizYoungStrat) January 26, 2023
My Comment of the Day
dougie kass I started the year with a contrarian view of an up (five to ten percent) first half and a down second half - ending the year exactly where we started on Jan 1 2023. The factors I cited in support of a better than consensus first half wer...
Tweet of the Day (Part Trois)
The Fed keeps saying they won't cut rates this year. The market disagrees and is doubling down on rate cuts by September. At the end of last year, traders were pricing a year-end fed funds rate of 4.6%. Today they're pricing in 4.4% by December. pic...
Chart of the Day
CHART OF THE DAY: We Can't Change The Past But We Can Learn From It https://t.co/TcIP2tEwgb via @hedgeye — Keith McCullough (@KeithMcCullough) January 25, 2023
Themes and Sectors
As noted daily, this table can serve as an important asset for short term traders: View Chart » View in New Window »
Oops!
We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.
Please Join or Log In to Email Our Authors.
Email Real Money's Wall Street Pros for further analysis and insight
Already a Subscriber? Login